SORRENTO THERAPEUTICS, INC. Form 8-K (Feb. 24, 2021)

Summary

Current report on Form 8-K for an event dated February 24, 2021, filed by Sorrento Therapeutics, Inc. Under Item 1.01, the report states that on February 24, 2021 Sorrento and ANP Technologies, Inc. entered into a binding term sheet under which Sorrento will, through a subsidiary, purchase all of the issued and outstanding equity of ANP. Contingent upon a definitive agreement, Sorrento will make an aggregate payment of $100,000,000, subject to certain adjustments, of which a minimum of $10,000,000 and up to $50,000,000 is payable in cash. ANP agreed to negotiate exclusively with Sorrento for 45 days. Henry Ji signed on March 1, 2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event
reported): February 24, 2021

SORRENTO THERAPEUTICS, INC.

(Exact Name of Registrant as Specified
in its Charter)

Delaware | 001-36150 | 33-0344842
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.)

4955 Directors Place

San Diego , CA 92121

(Address of Principal Executive Offices)
(Zip Code)

Registrant’s telephone number,
including area code: ( 858 ) 203-4100

N/A

(Former Name, or Former Address, if Changed
Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol | Name of each exchange on which registered
Common Stock, $0.0001 par value | SRNE | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01. Entry into a Material Definitive
Agreement.

On February 24, 2021, Sorrento Therapeutics,
Inc. (“Sorrento”) and ANP Technologies, Inc. (“ANP”) entered into a binding term sheet (the “Binding
Term Sheet”) setting forth the terms and conditions by which Sorrento will, through a subsidiary, purchase all of the issued
and outstanding equity of ANP (the “Acquisition”). Contingent upon the execution of a definitive agreement between
the parties (the “Definitive Agreement”) and subject to certain conditions, Sorrento will, at the closing of the Acquisition
(the “Closing”), make an aggregate payment of $100,000,000 (the “Base Purchase Price”), subject to certain
adjustments (the Base Purchase Price as so adjusted, the “Merger Consideration”). A minimum of $10,000,000 and up to
$50,000,000 of the Merger Consideration is payable by Sorrento in cash, subject to certain conditions, with the remainder payable
in shares of Sorrento common stock and the number of shares to be issued in respect thereof shall be determined based on the volume
weighted average price of the shares of Sorrento common stock traded on The NASDAQ Stock Market LLC for the seven consecutive trading
days’ beginning three trading days preceding the execution date of the Definitive Agreement and ending three trading days
following such execution date.

Under the Binding Term Sheet, ANP has agreed
to negotiate exclusively with Sorrento with respect to the Acquisition for a period of 45 days.

The final terms of the Acquisition are
subject to the negotiation and finalization of the Definitive Agreement and any other agreements relating to the Acquisition, and
the material terms of the Acquisition may differ from those set forth in the Binding Term Sheet. In addition, the Closing will
be subject to various customary and other closing conditions.

The foregoing description of terms of the
Binding Term Sheet does not purport to be complete and is qualified in its entirety by reference to the full text of the Binding
Term Sheet. A copy of the Binding Term Sheet will be filed with the Securities and Exchange Commission as an exhibit to Sorrento’s
Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 or via an amendment to this Current Report on Form 8-K.

Item 9.01. Financial Statements and
Exhibits.

(d) Exhibit.

104 | Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SORRENTO THERAPEUTICS, INC.
Date: March 1, 2021 | By: | /s/ Henry Ji, Ph.D.
Name: Henry Ji, Ph.D.
Title: Chairman of the Board, President and Chief Executive Officer

File and source

File

SEC_SRNE_8-K_filed2021-03-01_0001104659-21-029554.htm

Size

26,325 bytes

SHA-256

61529486cf5315e898b004941cb40177859bc836e902a038a7ca9463017477de

Our copy

SEC_SRNE_8-K_filed2021-03-01_0001104659-21-029554.htm

Original

www.sec.gov